+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Hela cells, 231 cells, K562 cells, human fetal brain tissue, Primary antibody: P11815(H2AC4 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P11815(H2AC4 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P11815(H2AC4 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The H2AC4 antibody targets histone H2A type 4 (H2AC4), a core component of nucleosomes responsible for DNA packaging and epigenetic regulation. As part of the H2A histone family, H2AC4 plays a critical role in maintaining chromatin structure and modulating gene expression through post-translational modifications (e.g., acetylation, phosphorylation). Antibodies against H2AC4 are widely used to study its localization, expression, and interactions in cellular processes such as DNA repair, replication, and transcriptional regulation.

These antibodies are essential tools in techniques like chromatin immunoprecipitation (ChIP), immunofluorescence (IF), and Western blotting to investigate histone dynamics in developmental biology, cancer research, and epigenetic studies. For example, altered H2AC4 expression or modification patterns have been linked to diseases, including cancers, where chromatin remodeling is dysregulated. Most H2AC4 antibodies are raised in rabbits or mice using peptide antigens corresponding to conserved regions of the protein, and specificity is validated via knockout controls or competitive assays. Researchers prioritize antibodies with high affinity and minimal cross-reactivity to other H2A variants (e.g., H2AZ or H2AX) to ensure accurate experimental outcomes. Understanding H2AC4's role through such antibodies contributes to insights into chromatin-related mechanisms and therapeutic targeting.